Association between MnSOD, CAT, and GPX1 genetic polymorphisms and risk of prostate cancer stratified by ROS exposures in Caucasians
| . | Cases . | Controls . | OR (95% CI)* . | Cases . | Controls . | OR (95% CI)* . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vitamin supplement . | Yes . | . | . | No . | . | . | ||||||
| MnSOD | ||||||||||||
| TT | 29 (18.0) | 114 (24.4) | 1.0 (ref) | 83 (28.2) | 179 (24.0) | 2.1 (1.23-3.47) | ||||||
| TC | 93 (57.8) | 228 (48.8) | 1.7 (1.05-2.88) | 146 (49.7) | 381 (51.1) | 1.7 (1.03-2.73) | ||||||
| CC | 39 (24.2) | 125 (26.8) | 1.3 (0.72-2.30) | 65 (21.1) | 186 (24.9) | 1.5 (0.89-2.60) | ||||||
| CAT | ||||||||||||
| CC | 93 (57.1) | 293 (61.4) | 1.0 (ref) | 188 (62.7) | 439 (58.2) | 1.4 (1.03-1.88) | ||||||
| CT | 59 (36.2) | 158 (33.1) | 1.1 (0.75-1.66) | 98 (32.7) | 286 (37.9) | 1.1 (0.79-1.57) | ||||||
| TT | 11 (6.8) | 26 (5.5) | 1.2 (0.56-2.71) | 14 (4.7) | 30 (4.0) | 1.5 (0.76-3.14) | ||||||
| GPX1 | ||||||||||||
| CC | 83 (51.2) | 238 (50.6) | 1.0 (ref) | 144 (49.7) | 377 (50.3) | 1.1 (0.80-1.55) | ||||||
| CT | 73 (45.1) | 198 (42.1) | 1.0 (0.69-1.48) | 117 (40.3) | 317 (42.3) | 1.1 (0.75-1.49) | ||||||
| TT | 6 (3.7) | 34 (7.2) | 0.4 (0.16-1.13) | 29 (10.0) | 56 (7.5) | 1.6 (0.95-2.82) | ||||||
| Smoking status | Never or former | Current | ||||||||||
| MnSOD | ||||||||||||
| TT | 52 (23.2) | 145 (25.5) | 1.0 (ref) | 60 (26.0) | 148 (23.0) | 1.0 (0.65-1.62) | ||||||
| TC | 119 (53.1) | 291 (51.1) | 1.1 (0.77-1.70) | 120 (52.0) | 319 (49.5) | 1.0 (0.65-1.44) | ||||||
| CC | 53 (23.7) | 133 (23.4) | 1.0 (0.62-1.62) | 51 (22.0) | 178 (27.5) | 0.8 (0.49-1.24) | ||||||
| CAT | ||||||||||||
| CC | 138 (60.0) | 348 (60.3) | 1.0 (ref) | 143 (61.4) | 384 (58.5) | 0.9 (0.66-1.18) | ||||||
| CT | 77 (33.5) | 200 (34.7) | 1.0 (0.68-1.35) | 80 (34.3) | 245 (37.4) | 0.8 (0.53-1.06) | ||||||
| TT | 15 (6.5) | 29 (5.0) | 1.2 (0.61-2.49) | 10 (4.3) | 27 (4.1) | 0.9 (0.44-2.04) | ||||||
| GPX1 | ||||||||||||
| CC | 116 (51.8) | 278 (48.6) | 1.0 (ref) | 111 (48.7) | 338 (52.1) | 0.7 (0.54-1.03) | ||||||
| CT | 92 (41.1) | 249 (43.5) | 0.9 (0.63-1.23) | 98 (43.0) | 266 (41.0) | 0.8 (0.57-1.12) | ||||||
| TT | 16 (7.1) | 45 (7.9) | 0.8 (0.40-1.47) | 19 (8.3) | 45 (6.9) | 1.0 (0.58-1.92) | ||||||
| BMI | <30.0 | ≥30.0 | ||||||||||
| MnSOD | ||||||||||||
| TT | 82 (24.7) | 205 (23.4) | 1.0 (ref) | 30 (25.0) | 87 (26.3) | 0.9 (0.52-1.47) | ||||||
| TC | 176 (53.0) | 449 (51.3) | 1.0 (0.72-1.38) | 62 (51.7) | 158 (47.7) | 1.0 (0.67-1.51) | ||||||
| CC | 74 (22.3) | 221 (25.3) | 0.8 (0.57-1.24) | 28 (23.3) | 86 (26.0) | 0.8 (0.47-1.36) | ||||||
| CAT | ||||||||||||
| CC | 205 (61.2) | 526 (59.6) | 1.0 (ref) | 75 (60.0) | 201 (58.8) | 1.0 (0.70-1.34) | ||||||
| CT | 112 (33.4) | 316 (35.8) | 0.9 (0.68-1.20) | 43 (34.4) | 126 (36.8) | 0.8 (0.56-1.25) | ||||||
| TT | 18 (5.4) | 41 (4.6) | 1.1 (0.57-1.96) | 7 (5.6) | 15 (4.4) | 1.4 (0.53-3.51) | ||||||
| GPX1 | ||||||||||||
| CC | 166 (51.2) | 445 (50.8) | 1.0 (ref) | 60 (48.0) | 168 (49.8) | 1.0 (0.70-1.34) | ||||||
| CT | 136 (42.0) | 366 (41.8) | 1.0 (0.75-1.31) | 52 (41.6) | 146 (43.3) | 0.9 (0.56-1.25) | ||||||
| TT | 22 (6.8) | 65 (7.4) | 0.8 (0.48-1.46) | 13 (10.4) | 23 (6.8) | 1.7 (0.53-3.51) | ||||||
| . | Cases . | Controls . | OR (95% CI)* . | Cases . | Controls . | OR (95% CI)* . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vitamin supplement . | Yes . | . | . | No . | . | . | ||||||
| MnSOD | ||||||||||||
| TT | 29 (18.0) | 114 (24.4) | 1.0 (ref) | 83 (28.2) | 179 (24.0) | 2.1 (1.23-3.47) | ||||||
| TC | 93 (57.8) | 228 (48.8) | 1.7 (1.05-2.88) | 146 (49.7) | 381 (51.1) | 1.7 (1.03-2.73) | ||||||
| CC | 39 (24.2) | 125 (26.8) | 1.3 (0.72-2.30) | 65 (21.1) | 186 (24.9) | 1.5 (0.89-2.60) | ||||||
| CAT | ||||||||||||
| CC | 93 (57.1) | 293 (61.4) | 1.0 (ref) | 188 (62.7) | 439 (58.2) | 1.4 (1.03-1.88) | ||||||
| CT | 59 (36.2) | 158 (33.1) | 1.1 (0.75-1.66) | 98 (32.7) | 286 (37.9) | 1.1 (0.79-1.57) | ||||||
| TT | 11 (6.8) | 26 (5.5) | 1.2 (0.56-2.71) | 14 (4.7) | 30 (4.0) | 1.5 (0.76-3.14) | ||||||
| GPX1 | ||||||||||||
| CC | 83 (51.2) | 238 (50.6) | 1.0 (ref) | 144 (49.7) | 377 (50.3) | 1.1 (0.80-1.55) | ||||||
| CT | 73 (45.1) | 198 (42.1) | 1.0 (0.69-1.48) | 117 (40.3) | 317 (42.3) | 1.1 (0.75-1.49) | ||||||
| TT | 6 (3.7) | 34 (7.2) | 0.4 (0.16-1.13) | 29 (10.0) | 56 (7.5) | 1.6 (0.95-2.82) | ||||||
| Smoking status | Never or former | Current | ||||||||||
| MnSOD | ||||||||||||
| TT | 52 (23.2) | 145 (25.5) | 1.0 (ref) | 60 (26.0) | 148 (23.0) | 1.0 (0.65-1.62) | ||||||
| TC | 119 (53.1) | 291 (51.1) | 1.1 (0.77-1.70) | 120 (52.0) | 319 (49.5) | 1.0 (0.65-1.44) | ||||||
| CC | 53 (23.7) | 133 (23.4) | 1.0 (0.62-1.62) | 51 (22.0) | 178 (27.5) | 0.8 (0.49-1.24) | ||||||
| CAT | ||||||||||||
| CC | 138 (60.0) | 348 (60.3) | 1.0 (ref) | 143 (61.4) | 384 (58.5) | 0.9 (0.66-1.18) | ||||||
| CT | 77 (33.5) | 200 (34.7) | 1.0 (0.68-1.35) | 80 (34.3) | 245 (37.4) | 0.8 (0.53-1.06) | ||||||
| TT | 15 (6.5) | 29 (5.0) | 1.2 (0.61-2.49) | 10 (4.3) | 27 (4.1) | 0.9 (0.44-2.04) | ||||||
| GPX1 | ||||||||||||
| CC | 116 (51.8) | 278 (48.6) | 1.0 (ref) | 111 (48.7) | 338 (52.1) | 0.7 (0.54-1.03) | ||||||
| CT | 92 (41.1) | 249 (43.5) | 0.9 (0.63-1.23) | 98 (43.0) | 266 (41.0) | 0.8 (0.57-1.12) | ||||||
| TT | 16 (7.1) | 45 (7.9) | 0.8 (0.40-1.47) | 19 (8.3) | 45 (6.9) | 1.0 (0.58-1.92) | ||||||
| BMI | <30.0 | ≥30.0 | ||||||||||
| MnSOD | ||||||||||||
| TT | 82 (24.7) | 205 (23.4) | 1.0 (ref) | 30 (25.0) | 87 (26.3) | 0.9 (0.52-1.47) | ||||||
| TC | 176 (53.0) | 449 (51.3) | 1.0 (0.72-1.38) | 62 (51.7) | 158 (47.7) | 1.0 (0.67-1.51) | ||||||
| CC | 74 (22.3) | 221 (25.3) | 0.8 (0.57-1.24) | 28 (23.3) | 86 (26.0) | 0.8 (0.47-1.36) | ||||||
| CAT | ||||||||||||
| CC | 205 (61.2) | 526 (59.6) | 1.0 (ref) | 75 (60.0) | 201 (58.8) | 1.0 (0.70-1.34) | ||||||
| CT | 112 (33.4) | 316 (35.8) | 0.9 (0.68-1.20) | 43 (34.4) | 126 (36.8) | 0.8 (0.56-1.25) | ||||||
| TT | 18 (5.4) | 41 (4.6) | 1.1 (0.57-1.96) | 7 (5.6) | 15 (4.4) | 1.4 (0.53-3.51) | ||||||
| GPX1 | ||||||||||||
| CC | 166 (51.2) | 445 (50.8) | 1.0 (ref) | 60 (48.0) | 168 (49.8) | 1.0 (0.70-1.34) | ||||||
| CT | 136 (42.0) | 366 (41.8) | 1.0 (0.75-1.31) | 52 (41.6) | 146 (43.3) | 0.9 (0.56-1.25) | ||||||
| TT | 22 (6.8) | 65 (7.4) | 0.8 (0.48-1.46) | 13 (10.4) | 23 (6.8) | 1.7 (0.53-3.51) | ||||||
ORs adjusting for age at enrollment, history of prostate cancer in first-degree relative, random assignment, smoking status (current versus former or nonsmoker), pack-years smoked (<40, 40-60, ≥60), alcohol consumption (nondrinker, below median, at or above median) and vitamin supplement use in logistic regression model.